BPG is committed to discovery and dissemination of knowledge
Articles in Press
4/23/2026 8:43:35 AM | Browse: 8 | Download: 0
Publication Name World Journal of Gastroenterology
Manuscript ID 119222
Country Italy
Category Gastroenterology & Hepatology
Manuscript Type Meta-Analysis
Article Title Limosilactobacillus reuteri DSM 17938 and PTA 6475 as adjunct in Helicobacter pylori therapy: Systematic review and meta-analysis
Manuscript Source Unsolicited Manuscript
All Author List Ruggiero Francavilla, Andrea Iannone, Fernanda Cristofori, Alessia Cafforio, Vanessa N Dargenio, Giovanni La Grasta, Viviana F Brindicci, Stefania P Castellaneta and Michele Barone
Funding Agency and Grant Number
Corresponding Author Ruggiero Francavilla, Full Professor, MD, PhD, Interdisciplinary Department of Medicine, Pediatric Section, Children’s Hospital ‘Giovanni XXIII’, University of Bari “Aldo Moro”, Via Giovanni Amendola, 207, Bari 70126, Puglia, Italy. ruggiero.francavilla@uniba.it
Key Words Helicobacter pylori; Limosilactobacillus reuteri; DSM 17938; PTA 6475; Probiotics; Antibiotic-associated side effects; Meta-analysis
Core Tip Helicobacter pylori (H. pylori) eradication therapy often causes multiple gastrointestinal side effects, limiting adherence. Probiotics, particularly Limosilactobacillus reuteri (L. reuteri), have been suggested as adjuncts to improve tolerability during standard eradication regimens. Our meta-analysis showed L. reuteri supplementation significantly reduced diarrhea, nausea, and dysgeusia during eradication therapy, though without enhancing eradication rates. Benefits were consistent and clinically meaningful across randomized trials. Precision probiotics, such as L. reuteri DSM 17938, may improve patient comfort, adherence, and treatment continuity by reducing side effects, representing a promising supportive strategy in H. pylori management.
Citation Francavilla R, Iannone A, Cristofori F, Cafforio A, Dargenio VN, La Grasta G, Brindicci VF, Castellaneta SP, Barone M. Limosilactobacillus reuteri DSM 17938 and PTA 6475 as adjunct in Helicobacter pylori therapy: Systematic review and meta-analysis. World J Gastroenterol 2026; In press
Received
2026-01-22 02:43
Peer-Review Started
2026-01-22 02:43
First Decision by Editorial Office Director
2026-02-13 08:13
Return for Revision
2026-02-13 08:13
Revised
2026-02-27 21:53
Publication Fee Transferred
Second Decision by Editor
2026-04-23 02:38
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2026-04-23 08:43
Articles in Press
2026-04-23 08:43
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Copyright ©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com